TRVI as reported
- Net Income
- −$51M
Net Income · +8.1% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$53M
Free Cash Flow · trailing twelve months to Q2 2026
- EPS
- −$0.34
EPS · −19% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$51M | +8.1% | Q2 2026 |
| EPS | −$0.34 | −19% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −21% | n/a | Q2 2026 |
| Free Cash Flow | −$53M | n/a | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Trevi Therapeutics, Inc. (TRVI) - Net IncomeNet IncomeTrevi Therapeutics, Inc. (TRVI)